Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.